Boston Pain Clinic & Primary Care PC
Boston Pain Clinic & Primary Care PC was paid $3.08M by Medicaid between Jan 2018 and Nov 2024, across 52 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 48% of everything it billed.
33Billing provider infoBOSTON PAIN CLINIC & PRIMARY CARE PC
HYDE PARK, MA 02136
HYDE PARK, MA 02136
33aNPI1790810745assigned 02/22/2007
33bProvider typeSpecialist
28Total paid$3.08M
24GClaims253,614
24DCodes billed52
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in Massachusetts
Rank by total paid#6 of 179
Median peer was paid$23K
This provider vs. median133×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,856 | $344K | |
| 2019 | 45,307 | $416K | |
| 2020 | 44,064 | $423K | |
| 2021 | 38,765 | $568K | |
| 2022 | 34,360 | $541K | |
| 2023 | 30,240 | $454K | |
| 2024incomplete | 22,022 | $332K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 48% | 34,389 | 31,228 | $1.49M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 18% | 7,216 | 6,792 | $542K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 19,980 | 18,533 | $379K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.2% | 3,685 | 3,060 | $99K |
| 64493 | 2.7% | 1,013 | 968 | $83K | |
| 62323 | 2.5% | 839 | 807 | $78K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 5,540 | 1,655 | $69K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.7% | 5,595 | 1,712 | $53K |
| 64494 | 1.3% | 1,004 | 954 | $40K | |
| 64495 | 1.3% | 967 | 923 | $39K | |
| 77003 | <1% | 3,231 | 3,019 | $26K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 5,783 | 5,361 | $24K |
40 more codes
| 20610 | <1% | 1,022 | $20K | |
| 99406 | <1% | 6,623 | $18K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 260 | $17K |
| 77002 | <1% | 910 | $16K | |
| 80305 | <1% | 2,944 | $14K | |
| 97161 | <1% | 420 | $12K | |
| 97164 | <1% | 364 | $12K | |
| 97014 | <1% | 1,539 | $9K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,269 | $9K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 115 | $7K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 538 | $4K |
| 1006F | <1% | 21,718 | $3K | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 21,608 | $2K |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | <1% | 14,346 | $2K |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 17,690 | $2K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 608 | $2K |
| 1036F | <1% | 15,793 | $2K | |
| 3016F | <1% | 21,571 | $2K | |
| 97035 | <1% | 210 | $1K | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | <1% | 11,363 | $1K |
| G9251 | Documentation of patient with pain not brought to a comfortable level within 48 hours from initial assessment | <1% | 5,445 | $946.42 |
| 97010 | <1% | 1,051 | $934.31 | |
| 96130 | <1% | 553 | $523.96 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | <1% | 2,325 | $486.70 |
| 96132 | <1% | 204 | $326.71 | |
| 4004F | <1% | 5,694 | $258.25 | |
| 96138 | <1% | 494 | $193.04 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15 | $155.09 |
| 99442 | <1% | 15 | $123.50 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | <1% | 5,630 | $100.62 |
| G8421 | Bmi not documented and no reason is given | <1% | 701 | $50.52 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 16 | $39.51 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15 | $17.43 |
| G8785 | Blood pressure reading not documented, reason not given | <1% | 678 | $16.68 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 55 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 48 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 219 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 47 | $0.00 |
| G9250 | Documentation of patient pain brought to a comfortable level within 48 hours from initial assessment | 0% | 224 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFELIZ, ROBERTO (PAIN MANAGMENT)